Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

K. Choueiri, Toni; Tomczak, Piotr; Hoon Park, Se; Venugopal, Balaji; Ferguson, Thomas; Chang, Yen‐Hwa; Hájek, Jaroslav; N. Symeonides, Stefan; Lee, Jae‐Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross‐Goupil, Marine; Mahave, Mauricio; B. Haas, Naomi; Sawrycki, Piotr; Gurney, Howard; Chevreau, Christine; Melichar, Bohuslav; Kopyltsov, Evgeniy; Alva, Ajjai; M. Burke, John; K. Doshi, Gurjyot; Topart, Delphine; Oudard, Stéphane; J. Hammers, Hans; Kitamura, Hiroshi; Bedke, Jens; F. Perini, Rodolfo; Zhang, Pingye; Imai, Kentaro; Willemann-Rogerio, Jaqueline; I. Quinn, David; Powles, Thomas

doi:10.1056/nejmoa2106391

Public

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Published in New England Journal of Medicine • Aug 18, 2021

Authors:

Toni K. Choueiri

Piotr Tomczak

Se Hoon Park

Abstract

BACKGROUND: Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. METHODS: In a double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with clear-cell renal-c...

Subject

Pembrolizumab

Renal cell carcinoma

Nephrectomy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!